The results from the present studies provide a foundation for the potential exploitation of the regulation of SIRT3 and the p53/TIGAR axis, especially targeting a reduction in p53/TIGAR to ameliorate or reverse diabetic cardiomyopathy. Here, TP53 is linked to diabetic cardiomyopathy.